AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02036515 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Insulin
Description: Insulin glargine rescue medication, injectable, as required. In the event that an investigator considers use of glimepiride to not be appropriate for a participant meeting protocol specified glycemic rescue criteria, insulin glargine can be initiated as the rescue medication, and managed by the investigator according to clinical practice guidelines of the local country.
Study NCT02036515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ertugliflozin 10 mg
Description: Matching placebo for ertugliflozin 10 mg, oral, once daily for 52 weeks
Study NCT06217679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Oral Glucose Tolerance Test
Description: control oral glucose tolerance test
Study NCT06217679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed Exercise
Description: exercise performed in randomized order
Study NCT03897621 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the placebo group will receive normal saline (a bolus of sodium chloride 0.9%, 0.1 mL/kg or maximal dose of 10 mL).
Study NCT01460472 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Racotumomab
Description: Patients will receive best support treatment and vaccination with racotumomab. The vaccination schedule is as follows: 5 doses (1mg/mL each), intradermally, every 2 weeks (induction period) followed by monthly vaccinations until any criteria for discontinuation are met. If disease progression occurs and further onco-specific therapy is indicated, the patient will be able to continue in the study and vaccination will not be interrupted unless criteria for vaccine discontinuation are met.
Study NCT01460472 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Support Treatment
Description: Patients will receive best support treatment for advanced NSCLC as per each institution's standards, including onco-specific therapies when disease progresses.
Study NCT01968317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol acetate and metformin
Description: Patients will receive metformin 500 mg by mouth third daily and megestrol acetate 160 mg by mouth daily for 3 months.
Study NCT01968317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol acetate
Description: Patients will receive megestrol acetate 160 mg by mouth daily for 3 months.
Study NCT02525978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Task
Description: Subjects are asked to watch a series of six two-minute video clips. The video clips are designed to induce sad or happy emotions or no emotion (neutral) and are taken from movies, documentaries, or instructional videos. There are two videos for each emotion condition. Videos and fixation cross screens are viewed on a laptop computer. In between video clips, patients are asked to quietly look at a fixation cross for one minute, describe their emotional reaction to the video for up to one minute, then again attend to a fixation cross for one minute. A video recording of the frontal view of the participant's face will be made during task performance.
Study NCT02525978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaginal Task
Description: Subjects are asked to think about happy or sad memories for 2 minutes. Subjects are asked to imagine performing neutral tasks, such as buying groceries. Subjects are then asked to think about a memory that makes them feel angry. A video recording of the frontal view of the participant's face will be made during task performance.
Study NCT06493747 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined Low- and High-Frequency rTMS Intervention
Description: This intervention involves the application of rTMS using an 8-shaped coil with a frequency of 1Hz for low-frequency stimulation and 5Hz for high-frequency stimulation, in accordance with the study protocol.
Study NCT06493747 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined High- and Low-Frequency rTMS Intervention
Description: Similar to Arm A, but the sequence of low and high-frequency rTMS is reversed.
Study NCT06493747 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Participants receive an individualized rTMS therapy plan based on integrated analysis of assessment data, targeting specific brain areas to enhance language function recovery post-stroke.
Study NCT06493747 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS + Acupuncture
Description: Participants undergo a combined treatment of rTMS as described for the rTMS Experimental Group and traditional Chinese acupuncture based on the Kaiqiao Jieyan method, targeting specific acupoints to facilitate recovery.
Study NCT06493747 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: Participants receive a conventional rTMS treatment as per established guidelines, serving as an active comparator to the experimental interventions.
Study NCT06493747 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Participants receive Kaiqiao Jieyan acupuncture therapy alone, without rTMS, following traditional Chinese medicine protocols for post-stroke aphasia rehabilitation.
Study NCT01014091 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK pandemic vaccine GSK2340272A
Description: 2 intramuscular injections
Study NCT00374205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine
Description: Artemether 20 mg/Lumefantrine 120mg fixe-dose-combination tablets: 3 days twice daily weight-adjusted dosing according to manufacturer
Study NCT05145114 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: THERAPEUTIC POSITIONS
Description: Therapeutic positioning includes placing infants in prone (prone), supine, side (lateral) decubitus, using restraint devices to provide support, reassurance and physiological stability.
Study NCT04226677 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: Treadmill training is include warming, cooling and training phase according to rating of perceived exertion for participants.
Study NCT04226677 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video based exercise
Description: Exergame training include virtual reality games by xbox kinect.
Study NCT04226677 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: first and last evaluations will be made
Study NCT04525820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single high dose vitamin D
Description: Patient receives either one dose orally of 140'000 IU (7 ml) of this drug once as an intervention treatment additionally to TAU or the patient receives 7 ml of the placebo Solution (7 ml) in addition to TAU
Study NCT04525820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient receives a single dose of a placebo solution
Study NCT04525820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment as usual vitamin D
Description: Both groups receive the treatment as usual after the single high dose or the placebo which will be 800 IU per day
Study NCT04525820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as usual vitamin D
Description: Both groups receive the treatment as usual after the single high dose or the placebo which will be 800 IU per day
Study NCT01403584 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AutoVPAP with addition of AutoEPAP
Description: Implementation of automated algorithm for adjustment of conventional device parameter (EPAP0.
Study NCT01403584 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AutoVPAP with addition of AutoEPAP
Description: Implementation of automated algorithm for adjustment of conventional device parameter (EPAP0.
Study NCT01403584 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AutoVPAP with EPAP manually selected
Description: Conventionally applied Expiratory Positive Airway Pressure (EPAP)
Study NCT01403584 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AutoVPAP with EPAP manually selected
Description: Conventionally applied Expiratory Positive Airway Pressure (EPAP)
Study NCT02402751 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acquisition of normative database with ultra high field MRI
Description: characterize non-invasively with an unprecedented resolution and sensitivity (high field MRI), anatomy as well as certain physiological, hemodynamic and metabolic function of brain, spinal cord, musculoskeletal system, and heart
Study NCT02402751 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Study NCT04743050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fatty Acids, Unsaturated
Description: All participants from Experimental Groups will receive supplementation of different fractions of EFAs esters for six months daily. Control Group will be monitored with the same tests, but will not receive any supplementation.
Study NCT04419259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 334
Description: 30 subjects with rosacea will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8)
Study NCT04743050 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic Tests
Description: All participants will have laboratory tests marking: CRP, fasting glucose, lipid profile, total blood count, and additional tests, which will include blood pressure measurements and measurements of body mass and composition on a specialized body composition analyzer (InBody 270). All the mentioned tests will be performed at the time of joining the research program, after 3 months (in the middle of the research program) and after 6 months (at the end of the research program).
Study NCT03403842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sublingual sufentanil tablet system
Description: Administration of sublingual sufentanil with a PCA
Study NCT03403842 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peridural catheter
Description: Positioning of a peridural catheter with a continuous infusion of ropivacaine 0,2% 99 ml+sufentanil 50 mcg
Study NCT05406089 — intervention group
Intervention type: OTHER
Intervention: Medication history
Description: The study was retrospective and did not involve the application of interventions
Study NCT03301259 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One-shape rotationary system
Description: OneShape (MICRO-MEGA) rotary nickel-titanium use roation movement and available in two sizes N°30 - .06 rotary files. , N°25 - .06
Study NCT02522741 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting STAIR
Description: Parenting-STAIR is an adaptation of a 16 session study therapy entitled Skills Training in Affective and Interpersonal Regulation/Modified Prolonged Exposure (STAIR/MPE). It generally is comprised of approximately 23 sessions and includes seven didactic interaction parenting sessions. There are threskill building in areas such as e modules within Parenting STAIR: 1) Module 1 focuses on skill building (awareness of emotional states, management of negative feelings, regulation of emotional intensity, etc.); 2) Module 2 involves the processing of memories of trauma and creating a coherent and meaningful life narrative; 3) Module 3 includes both the mother and child, and focuses on increasing maternal attunement and improving parenting skills.
Study NCT01046942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel+acetylsalicylic acid
Description: loading dose clopidogrel 300mg on second postoperative day. Thereafter 75mg clopidogrel daily for 3 months Aspirin 75mg daily, started within 24 hours after surgery
Study NCT01046942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylsalicylic acid
Description: aspirin 75 mg daily, started 6-24 hours after surgery
Study NCT02789748 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesthetic stimulation
Description: Activation of mechanoreceptors by vibration bursts
Study NCT01303497 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: Day 1, 8 and 15 : Paclitaxel 90 mg/m², IV over 1h, during 6 cycles (1 cycle = 28 days)
Study NCT01303497 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: Bevacizumab until progression or inacceptable toxicity :~* During the cycles of chemotherapy : Day 1 and D15 : 10 mg/kg,IV~* After 6 cycles of chemotherapy : 15 mg/kg, IV
Study NCT01402726 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: renal sympathetic modification
Description: Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
Study NCT03318458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: The duration of the intervention is 12 weeks, with 2 sessions per week of Pilates. Each session lasts approximately 1 hour and is structured in three parts: initial warm-up, which reviews the basic principles of the Pilates Method (centralization, concentration, movement control, breathing, movement precision and fluency) of 10 minutes duration, a 40-45 minute Pilates session and finally 10 minutes of guided relaxation. No complement was used (magic rings, fitball, elastic bands, etc.) during classes
Study NCT01349387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: After inclusion in the study to J0, metformin treatment will be interrupted between J1 and J30, replaced by Januvia 100 mg/day dose, then resumed at J31.
Study NCT02768181 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition-specific Behaviour change communication (BCC)
Description: Door-to-door counseling on nutrition during pregnancy and exclusive breastfeeding from enrolment into study till birth; exclusive breastfeeding and nutrition of lactating mothers during post-natal 6 months; timely and appropriate complementary feeding with continued breastfeeding until 2 years of child's age, and nutrition of lactating mothers during post-natal 6-24 months; all counseling would be supplemented with associated issues including hygiene and sanitation, mother's sleep and rest, maternal and child healthcare seeking etc.
Study NCT02768181 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrient supplement to pregnant women (PNS)
Description: A lipid-based micronutrient supplement (LNS) is packed in \~10g sachets. Formulation: Vegetable fat (soy), skimmed milk powder, peanuts, vitamin and mineral complex, sugar, stabilizer: fully hydrogenated vegetable fat, and antioxidant : tocopherols. Each sachet contains 70-75% of recommended dietary allowance for most of the micronutrients, including iron, folic acid, zinc, calcium, iodine, vitamins A, B1, B2, niacin, B12 etc.~Dose: 1 sachet/pregnant woman/day starting from the first counseling session (GA \~125∓15 days) continued till birth of baby. Supplement should be taken with food in room temperature, and must not be heated, or mixed with hot food. To avoid overdose, respondents receiving this supplement should stop taking any other micronutrient supplement or drink.
Study NCT03403842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PCA Morphine
Description: Administration of endovenous morphine with a PCA
Study NCT03603327 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Direct acting anti-viral agents
Description: Standard of care for Hepatitis C treatment
Study NCT02253927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 - D1
Study NCT02253927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 - D2
Study NCT02253927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 - D3
Study NCT02253927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 - D4
Study NCT02253927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Study NCT02253927 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high fat breakfast
Study NCT05255185 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: domino therapy
Description: The investigators evaluated routine blood test results, C-reactive protein level, the erythrocyte sedimentation rate, and other indicators. X-rays and CT scans of the surgical site were obtained and the Musculoskeletal Tumor Society (MSTS) score was calculated. Treatment involved debridement and lavage of the prosthesis, and systemic and local antibiotics.
Study NCT02973633 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diffusion Tensor MRI (DTI)
Description: Diffusion Tensor MRI (DTI) measures the diffusion of water in the heart, which allows the orientation of the muscle fibers in the heart to be determined.
Study NCT02973633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gadolinium DOTA Meglumine
Description: Late Gadolinium enhancement
Study NCT04474548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound use
Description: Ultrasound will be used to determine location of IUD after insertion.
Study NCT01894568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Peglispro
Description: Administered SC using a prefilled pen.
Study NCT01894568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered SC using a prefilled pen
Study NCT01894568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Antihyperglycemic Medications (OAMs)
Description: Administered orally
Study NCT01894568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Antihyperglycemic Medications (OAMs)
Description: Administered orally
Study NCT02685475 — intervention group
Intervention type: DRUG
Intervention: Axillary Brachial Plexus Blocks
Description: All patients received ultrasound-guided axillary brachial plexus block (ABPBs) with the mixture of 10 mL lidocaine 2% and 20 mL bupivacaine 0.5%.
Study NCT04743050 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic Tests
Description: All participants will have laboratory tests marking: CRP, fasting glucose, lipid profile, total blood count, and additional tests, which will include blood pressure measurements and measurements of body mass and composition on a specialized body composition analyzer (InBody 270). All the mentioned tests will be performed at the time of joining the research program, after 3 months (in the middle of the research program) and after 6 months (at the end of the research program).
Study NCT01780233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl 400 µg sublingual spray
Study NCT01780233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actiq® 400 µg transmucosally
Description: Actiq® 400 µg is a solid formulation of fentanyl citrate on a plastic stick that dissolves slowly in the mouth for absorption across the buccal mucosa.
Study NCT01780233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl citrate injection 100 µg intravenously
Study NCT01780233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone 50 mg
Description: Naltrexone hydrochloride was administered approximately 12 hours and 1 hour prior to and 12 hours after each dose of fentanyl to minimize the occurrence of unacceptable adverse effects (eg, decreased respiration, nausea) often associated with administration of fentanyl.
Study NCT01780233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg
Description: Naltrexone hydrochloride was administered approximately 12 hours and 1 hour prior to and 12 hours after each dose of fentanyl to minimize the occurrence of unacceptable adverse effects (eg, decreased respiration, nausea) often associated with administration of fentanyl.
Study NCT03530514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN4461
Description: REGN4461
Study NCT03530514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching REGN4461
Study NCT02768181 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrienr supplement to children 6m to 2 years
Description: A lipid-based micronutrient supplement (LNS) is packed in \~10g sachets. Formulation: Vegetable fat, skimmed milk powder, peanuts, sugar, vitamin and mineral complex, maltodextrin, and emulsifier: lecithin. Each sachet contains 70-75% of recommended dietary allowance for most of the micronutrients, including iron, folic acid, zinc, calcium, iodine, vitamins A, B1, B2, niacin, B12 etc. Each 20 g of LNS provide ≥4.46g LA (Linoleic Acid) and ≥0.42g ALA (α-Linolenic Acid).~Dose: 2 sachets \~(10+10=20g)/child/day from 5th completed months (181 days) to 24 completed months of child's age. Supplement should be taken with food in room temperature, and must not be heated, or mixed with hot food. Supplement should be taken with food in room temperature, and must not be heated, or mixed with hot food. To avoid overdose, respondents receiving this supplement should stop taking any other micronutrient supplement or drink.
Study NCT00473499 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: DEBlue vs Cypher vs BMS
Description: BMS vs DES vs DEB+BMS
Study NCT00473499 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DEBlue vs Cypher vs BMS
Description: BMS vs DES vs DEB+BMS
Study NCT00473499 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEBlue vs Cypher vs BMS
Description: BMS vs DES vs DEB+BMS
Study NCT01767220 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Strategy 1 - endocardial ablation
Description: VT substrate mapping and VT ablation are done only from endocardial. Therefore the catheters are introduced through the femoral veins/arteries. For mapping and ablation a 3,5 mm irrigated tip catheter (Navistar Thermocool, Biosense Webster, Diamond Bar, CA, USA) will be used.